Significance and management of micrometastases in patients with breast cancer

Expert Review of Anticancer Therapy

Volumn 7, Issue 10, 2007, Pages 1451-1461

  Mittendorf, Elizabeth A ^a   Hunt, Kelly K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Isolated tumor cell; Macrometastases; Micrometastases; Sentinel lymph node biopsy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; MICROMETASTASIS; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; TISSUE SECTION; TREATMENT CONTRAINDICATION; ADJUVANT CHEMOTHERAPY; AXILLA; BREAST TUMOR; DISEASE COURSE; DISEASE MANAGEMENT; FEMALE; LYMPHADENECTOMY; MULTICENTER STUDY; OBSERVER VARIATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE MANAGEMENT; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MULTICENTER STUDIES; NEOPLASM STAGING; OBSERVER VARIATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 35848966116     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.10.1451     Document Type: Review

References (69)

1. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann. Surg. 220(3), 391-398 (1994).
2. Albertini JJ, Lyman GH, Cox C et al. Lymphatic mapping and sentinel node biopsy in the patient with breast eancer. JAMA 276(22), 1818-1822 (1996).
3. Giuliano AE. Lymphatic mapping and sentinel node biopsy in breast cancer. JAMA 277(10), 791-792 (1997).
4. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Eagl. J. Med. 349(6), 546-553 (2003).
5. Giuliano AE. Sentinel lymphadenectomy in primary breast carcinoma: an alternative to routine axillary dissection. J. Surg. Oncol. 62(2), 75-77 (1996).
6. Veronesi U, Paganelli G, Galimberti V et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349 (9069), 1864-1867 (1997).
7. Singletary SE, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J. Clin. Oncol. 20(17), 3628-3636 (2002).
8. Breast, In: American Joint Committee on Cancer Cancer Staging Manual (6th Edition). Greene FL, Page DL, Fleming ID (Eds). Springer, NY, USA 223-240 (2002).
9. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer 98(12), 2740-2741 (2003).
10. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J. Clin. 56(1), 37-47 (2006).
11. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group, Lancet 335(8705), 1565-1568 (1990).
12. Cote RJ, Peterson HF, Chaiwun B et al. Role of immumohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 354 (9182), 896-900 (1999).
13. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br. J. Cancer 66(3), 523-527 (1992).
14. Noguchi S, Aihara T, Nakamori S et al. The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction, Cancer 74 (5), 1595-1600 (1994).
15. Sedmak DD, Meineke TA, Knechtges DS, Anderson J. Prognostic significance of cytokeratin-positive breast cancer metastases. Mod. Pathol. 2(5), 516-520 (1989).
16. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br. J. Cancer 55(3), 303-306 (1987).
17. Boughey JC, Bedrosian I, Meric-Bernstam F et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am. Coll. Surg. 203(4), 475-480 (2006).
18. Cox C, White L, Allred N et al. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann. Surg. Oncol. 13(5), 708-711 (2006).
19. Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 88(5), 1099-1107 (2000).
20. Weaver DL, Krag DN, Manna EA et al. Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. An NSABP protocol B-32 qualitv assurance Study. Cancer 107(4). 661-667 (2006).
21. Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124(7), 966-978 (2000).
22. Lyman GH, Giuliano AE, Somerfield MR et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J. Clin. Oncol. 23(30), 7703-7720 (2005).
23. Viale G, Bosari S, Mazzarol G et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 85(11), 2433-2438 (1999).
24. Viale G, Maiorano E, Mazzarol G et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 92(6), 1378-1384 (2001).
25. Yared MA, Middleton LP, Smith TL et al. Recommendations for sentinel lymph node processing in breast cancer. Am. J. Surg. Pathol. 26(3), 377-382 (2002).
26. Cserni G, Bianchi S, Boecker W et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 103, 358-367 (2005).
27. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for nodi-negative breast cancer. The Ludwig Breast Cancer Study Group. N. Engl. J. Med. 320(8), 491-496 (1989).
28. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J. Clin. 47(1), 28-51 (1997).
29. Fisher B, Bauer M, Wickerham DL et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52(9), 1551-1557 (1983).
30. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 42(4), 2025-2031 (1978).
31. Huvos AG, Hutter RV, Berg JW. Significance of axillary macrometastases and micrometastases in mammarv cancer. Ann. Surg. 173(1), 44-46 (1971).
32. Pickren JW. Significance of occult metastases. A study of breast cancer. Cancer 14, 1266-1271 (1961).
33. Maibenco DC, Dombi GW, Kau TY, Severson RK. Significance of micrometastases on the survival of women with T1 breast cancer. Cancer 107(6), 1234-1239 (2006).
34. Friedman S, Bertin F, Mouriesse H et al. Importance of tumor cells in axillary node sinus margins ('clandestine' metastases) discovered by serial sectioning in operable breast carcinoma. Acta Oncol. 27(5), 483-487 (1988).
35. Hainsworth PJ, Tjandra JJ, Stillwell RG et al. Detection and significance of occult metastases in node-negative breast cancer. Br. J. Surg. 80(4), 459-463 (1993).
36. McGuckin MA, Cummings MC, Walsh MD, Hohn BG, Bennett IC, Wright RG. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br. J. Cancer 73 (1), 88-95 (1996).
37. Nasser IA, Lee AK, Bosari S, Saganich R; Heatley G, Silverman ML. Occult axillary lymph node metastases in "node-negative" breast carcinoma. Hum. Pathol. 24(9), 950-957 (1993).
38. Wilkinson EJ, Hause LL, Hoffman RG et al. Occult axillary lymph node metastases in invasive breast carcinoma: characteristics, of the primary tumor and significance of the metastases. Pathol. Annu. 17(Pt 2), 67-91 (1982).
39. Querzoli P, Pedriali M, Rinaldi R et al. Axillary lymph node nanornetastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin. Cancer Res. 12(22), 6696-6701 (2006).
40. Hansen NM, Grube BJ, Te W et al. Clinical significnace of axillary micrometastases in breast cancer: how small is too small? Proc. Am. Soc. Clin. Oncol. 20, A91 (2001).
41. Cox C, Vrcel V, Riker A et al. Significance of sentinel lymph node micrometastasis on survival for patients with invasive breast cancer. Break Cancer Res. Treat. 94, S12-S13 (2005).
42. Chagpar A, Middleton LP, Sahin AA et al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistrvy Cancer 103(8), 1581-1586 (2005).
43. Krag DN, Julian TB, Harlow SP et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann. Surg. Oncol. 11 (Suppl. 3), S208-S210, (2004).
44. Changsri C, Prakash S, Sandweiss L, Bose S. Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Breast J. 10(5), 392-397 (2004).
45. Giard S, Baranzelli MC, Robert D et al. Surgical implications of sentinel node with micrometastatic disease in invasive breast cancer. Eur. J. Surg. Oncol. 30(9), 924-929 (2004).
46. Hwang RF, Krishnamurthy S, Hunt KK et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann. Surg. Oncol. 10(3), 248-254 (2003).
47. Liang WC, Sickle-Santanello BJ, Nims TA. Is a completion axillary dissection indicated for micrometastases in the sentinel lymph node? Am. J Surg. 182(4), 365-368 (2001).
48. McCready DR, Yong WS, Ng AK, Miller N, Done S, Youngson B. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst. 96(11), 873-875 (2004).
49. Mignotte H, Treilleux I, Faure C, Nessah K, Bremond A. Axillary lymph-node dissection for positive sentinel nodes in breast cancer patients. Eur J. Surg. Oncol. 28(6), 623-626 (2002).
50. Nos C, Harding-MacKean C, Freneaux P et al. Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br. J. Surg. 90(11), 1354-1360 (2003).
51. Saidi RF, Dudrick PS, Remine SG, Mittal VK. Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer. Am. Surg. 70(2), 101-105 (2004).
52. van Rijk MC, Peterse JL, Nieweg OE, Oldenburg HS, Rutgers EJ, Kroon BB. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer 107(3), 467-471 (2006).
53. Weiser MR, Montgomery LL, Tan LK et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann. Surg. Oncol. 8(2), 145-149 (2001).
54. Zavagno G. De Salvo GL. Bozza F et al. Number of metastatic sentinel nodes as predictor of axillary involvement in patients with breast cancer. Breast Cancer Res. Treat. 86(2), 171-179 (2004).
55. Cserni G, Gregori.D. Merletti F et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br. J. Surg. 91(10), 1245-1252 (2004).
56. Viale G, Maiorano E, Pruneri G et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann. Surg. 241(2), 319-325 (2005).
57. Houvenaeghel G, Nos C, Mignotte H et al. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement - Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer. J. Clin. Oncol. 24(12), 1814-1822 (2006).
58. Chu KU, Turner RR, Hansen NM, Brennan MB, Giuliano AE. Sentinel node metastasis in patients with breast carcinoma accurately predicts imimmohistochemically detectable nonsentinel node metastasis. Ann. Surg. Oncol. 6(8), 756-761, (1999).
59. Czerniecki Bj, Scheff AM, Callans LS et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 85(5), 1098-1103 (1999).
60. Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J. 10(2), 101-105 (2004).
61. Reynolds C, Mick R, Donohue JH et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J. Clin. Oncol. 17(6), 1720-1726 (1999).
62. Turner RR, Chu KU, Qi K et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 89(3), 574-581 (2000).
63. Kamath VJ, Giuliano R, Dauway EL et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch. Surg, 136(6), 688-692 (2001).
64. Recht A, Edge SB. Evidence-based indications for postmastectomy irradiation. Surg. Clin. North Am. 83(4), 995-1013 (2003).
65. Recht A, Edge SB, Solin LJ et al. Postmastectorny radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19(5), 1539-1569 (2001).
66. Rivers AK, Griffith KA, Hunt KK et al. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann. Surg. Oncol. 13(l), 36-44, (2006).
67. Louis-Sylvestre C, Clough K, Asselain B et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin. Oncol. 22(1), 97-101 (2004).
68. Gadd M, Harris J, Taghian A et al. Prospective study of axillary radiation without axillary dissection for breast cancer patients with a positive sentinel node. Breast Cancer Res. Treat. 94(Suppl.), S13 (2005).
69. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).